Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.32 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.32 |
| ▸ | KRAS | P01116 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3406627 | 0.77 | PLA2G4A (0.41) | — | |
| SCHEMBL7006185 | 0.74 | HTR6 (0.46) | KDM4E | |
| SCHEMBL4142457 | 0.71 | MAPT (0.34) | SMN1; SMN2ALDH1A1GAALMNAMAPT | |
| SCHEMBL6510985 | 0.71 | PDE4B (0.33) | SMN1; SMN2ALDH1A1MAPTDNM1 | |
| SCHEMBL7010546 | 0.71 | HTR6 (0.44) | — | |
| SCHEMBL7012792 | 0.71 | HTR6 (0.44) | — | |
| SCHEMBL7010544 | 0.71 | HTR6 (0.44) | — | |
| SCHEMBL7006184 | 0.69 | SLC6A4 (0.36) | MAPT | |
| SCHEMBL3410215 | 0.69 | TSPO (0.42) | SMN1; SMN2KDM4EALDH1A1POLBKRAS | |
| SCHEMBL18191223 | 0.66 | MAPT (0.41) | SMN1; SMN2ALDH1A1GAALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816328-B2 | Substituted fused heterocyclic C-glycosides | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-19 | — | — | US | disclosed |
| US-20100004160-A1 | SUBSTITUTED FUSED HETEROCYCLIC C-GLYCOSIDES | RYBCZYNSKI PHILIP | 2010-01-07 | — | — | US | disclosed |
| US-20090105162-A1 | SUBSTITUTED FUSED HETEROCYCLIC C-GLYCOSIDES | RYBCZYNSKI PHILIP | 2009-04-23 | — | — | US | disclosed |
| US-7482330-B2 | Substituted fused heterocyclic C-glycosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-27 | — | — | US | disclosed |
| US-20060229260-A1 | Substituted fused heterocyclic C-glycosides | Tanabe Pharma Corporation (JP) | 2006-10-12 | — | — | US | disclosed |
| US-7094763-B2 | Substituted fused heterocyclic C-glycosides | JANSSEN PHARACEUTICA, N.V. (BE) | 2006-08-22 | — | — | US | disclosed |
| US-20050037980-A1 | Substituted fused heterocyclic C-glycosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004160-A1 | SUBSTITUTED FUSED HETEROCYCLIC C-GLYCOSIDES | UGCG, UGGT1, GCG | SMN1; SMN2 4012/4885KDM4E 3904/4885ALDH1A1 3466/4885 |
| US-20060229260-A1 | Substituted fused heterocyclic C-glycosides | UGCG, UGGT1, GCG | SMN1; SMN2 4012/4885KDM4E 3904/4885ALDH1A1 3466/4885 |
| US-20090105162-A1 | SUBSTITUTED FUSED HETEROCYCLIC C-GLYCOSIDES | UGCG, UGGT1, GCG | SMN1; SMN2 4012/4885KDM4E 3904/4885ALDH1A1 3466/4885 |
| US-20050037980-A1 | Substituted fused heterocyclic C-glycosides | UGCG, UGGT1, GCG | SMN1; SMN2 4012/4885KDM4E 3904/4885ALDH1A1 3466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.